Our own bioinformatics analyses and sequencing data corroborate these findings, demonstrating that FEN1 expression is markedly elevated in stage IV NB compared to earlier stages, suggesting its potential as a prognostic indicator for adverse outcomes in this cancer. This evidence concerns the gene FEN1 and neuroblastoma.